Unknown

Dataset Information

0

Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase.


ABSTRACT: Peripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed in many patients with Parkinson's disease. We evaluated the effect of levodopa/PDI use on serum AADC enzyme activity. Serum AADC enzyme activity was evaluated in three independent cohorts of patients with Parkinson's disease or parkinsonism (n = 301) and compared between patients on levodopa/PDI vs. patients not on this medication. AADC enzyme activity was elevated in 62% of patients on levodopa/PDI treatment, compared to 19% of patients not on levodopa/PDI (median 90 mU/L vs. 50 mU/L, p < 0.001). Patients with elevated AADC activity had longer disease duration and higher doses of levodopa/PDI. These findings may implicate that peripheral AADC induction could underlie a waning effect of levodopa, necessitating dose increases to maintain a sustained therapeutic effect.

SUBMITTER: van Rumund A 

PROVIDER: S-EPMC7979935 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8003434 | biostudies-literature
| S-EPMC6122029 | biostudies-literature
| S-EPMC7318280 | biostudies-literature
| S-EPMC6377184 | biostudies-literature
| S-EPMC3734303 | biostudies-literature
| S-EPMC7819234 | biostudies-literature
| S-EPMC8418346 | biostudies-literature
| S-EPMC5241937 | biostudies-literature
| S-EPMC6543696 | biostudies-literature
2021-03-31 | GSE153990 | GEO